SCHEMBL3614718

SCHEMBL3614718

O=C(Nc1cscc1C(=O)O)c1ccc(Cl)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS12 P56730 3/20 0.52
PTPN1 P18031 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
HPGD P15428 4/20 0.51
ALDH1A1 P00352 3/20 0.51
DAO P14920 1/20 0.50
NPC1 O15118 8/20 0.49
RAB9A P51151 8/20 0.49
KMT2A Q03164 7/20 0.49
MEN1 O00255 6/20 0.49
LMNA P02545 3/20 0.49
KDM4E B2RXH2 5/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614428 0.85 KMT2A (0.61) SMN1; SMN2HPGDALDH1A1NPC1RAB9A
SCHEMBL3620308 0.79 PRSS12 (0.51) PRSS12SMN1; SMN2HPGDALDH1A1DAO
SCHEMBL3618151 0.79 KDM4C (0.58) PRSS12SMN1; SMN2HPGDALDH1A1DAO
SCHEMBL4633611 0.79 KMT2A (0.48) PRSS12SMN1; SMN2HPGDALDH1A1DAO
SCHEMBL1308259 0.78 PRSS12 (0.63) PRSS12SMN1; SMN2HPGDALDH1A1KMT2A
SCHEMBL3616663 0.78 SMN1; SMN2 (0.50) PRSS12SMN1; SMN2HPGDALDH1A1DAO
SCHEMBL3617679 0.76 RAB9A (0.59) PRSS12SMN1; SMN2HPGDALDH1A1DAO
SCHEMBL3618064 0.74 NPC1 (0.60) PRSS12SMN1; SMN2HPGDALDH1A1DAO
SCHEMBL4634518 0.74 KMT2A (0.52) SMN1; SMN2HPGDALDH1A1NPC1RAB9A
SCHEMBL3622444 0.73 MEN1 (0.73) PRSS12PTPN1SMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2010-01-07 US disclosed
WO-2007028520-A1 IMINOOXAZOLIDINE DERIVATIVES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004292-A1 Iminooxazolidine Derivatives and Their Use PPOX, XDH, PNPO PRSS12 3975/4885PTPN1 2384/4885SMN1; SMN2 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.